^
Association details:
| Biomarker: | HER-2 amplification + PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).
Published date:
06/01/2018
Excerpt:
HER2+ (pre-T testing) PD-L1-unselected GEA pts were enrolled….Of 57 evaluable pts to date in expansion (30 NA and 27 A), best ORR was 16% and disease control rate (DCR) was 54%. Both ctDNA ERBB2 amp and PD-L1 positivity predicted response (24% vs. 0% [p = .0655] and 36% vs. 5% [p = .0367], respectively)....M+P is a well-tolerated regimen with antitumor activity in 2nd line HER2+ GEA.
DOI:
10.1200/JCO.2018.36.15_suppl.4030
Trial ID:
